Research
Good news for people newly diagnosed with rare autoimmune disorder: Study finds low relapse risk
The Brief
- People newly diagnosed with MOGAD generally had a low risk of relapse.
- They also generally had a low risk of lasting disability, according to a Kaiser Permanente study.
- The study was published in the journal Neurology.
Why it matters
The findings give clinicians and patients a more reassuring picture of likely outcomes soon after a MOGAD diagnosis.
Who’s affected
- neurologists and clinicians who treat MOGAD
- people newly diagnosed with MOGAD and their families
- #mogad
- #autoimmune
- #neurology
- #relapse
- #clinical-research
People newly diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, generally had a low risk of relapse and lasting disability, according to a Kaiser Permanente study. The work is published in the journal Neurology.